



Patent/  
Attorney's Docket No. 01895-452

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Nishizumi NISHIMUTA et al

Application No.: 10/046,575

Filed: January 16, 2002

For: EXTERNAL PREPARATION FOR SKIN  
DISEASES CONTAINING  
NITROIMIDAZOLE

Group Art Unit: 1614

Examiner: Unassigned

Confirmation No. 4939

RECEIVED  
NOV 15 2002  
CH CENTER 1600/2900

SECOND INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$\_\_\_\_\_ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

By: Susan M. Dadio

Susan M. Dadio  
Registration No. 40,373

Date: November 14, 2002



Patent  
Attorney's Docket No. 018995-452

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
)  
Nishizumi NISHIMUTA et al. ) Group Art Unit: 1614  
)  
Application No.: 10/046,575 ) Examiner: Unassigned  
)  
Filed: January 16, 2002 ) Confirmation No.: 4939  
)  
For: EXTERNAL PREPARATION FOR SKIN )  
DISEASES CONTAINING )  
NITROIMIDAZOLE )  
)

RECEIVED  
NOV 15 2002  
TECH CENTER 1600/2900

**SECOND  
INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

**OTHER NON-PATENT DOCUMENTS**

1. KOSTAKIS et al., "The Immunosuppressive Action of Metronidazole," *IRCS Medical Science*, 1977, p. 142, Vol. 5.
2. *Pharmacy*, 1996, pp. 1137-1141, Vol. 47, No. 8.

This Information Disclosure Statement contains information which is not in the English language. In accordance with M.P.E.P. § 609 A(3) a concise explanation of relevance for the non-English language information is as follows:

The *Pharmacy* article (47(8):1137-1141 (1996)) discloses that a pharmaceutical composition for external application containing cyclosporin (CsA) and tacrolimus (FK506) which are known to have immune suppressive effects at the organ transplantation are useful as a therapeutic agent for atopic dermatitis (Fig. 1 on page 1139).

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore under 37 C.F.R. § 1.97(b) no fee or statement is required.


To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: November 14, 2002

By:

  
\_\_\_\_\_  
Susan M. Dadio  
Registration No. 40,373

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

